Shares in Northwest Biotherapeutics (NASDAQ:NWBO), a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, have jumped 12% pre-market after the company said the Data Safety Monitoring Board has recommended its Phase III trial into a lethal form of brain cancer continue. The company’s lead program is a 312-patient Phase III trial in newly diagnosed Glioblastoma multiforme (GBM). Northwest Biotherapeutics (NASDAQ:NWBO)’s stock on … Continue reading Pre-Market Noise Makers: Northwest Biotherapeutics (NASDAQ:NWBO), Children’s Place (NASDAQ:PLCE), Cooper Companies (NYSE:COO), Verisk Analytics (NASDAQ:VRSK)